Open AccessInpatient Management of Mucocutaneous GVHD
Author(s) -
Toral Vaidya,
Christian Menzer,
Doris M. Ponce,
Alina Markova
Publication year - 2019
Publication title -
current dermatology reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.314
H-Index - 13
ISSN - 2162-4933
DOI - 10.1007/s13671-019-00280-3
Subject(s) - medicine , mucocutaneous zone , graft versus host disease , disease , hematopoietic stem cell transplantation , basiliximab , immunosuppression , ibrutinib , transplantation , immunology , intensive care medicine , dermatology , leukemia , tacrolimus , chronic lymphocytic leukemia
Graft-versus-host disease (GVHD) is an immune mediated disorder affecting 30 - 70% of patients after allogeneic hematopoietic stem cell transplantation (alloHSCT), and is a major cause of morbidity and non-relapse mortality (NRM) [1]. Dermatologists play a critical role in acute and chronic GVHD, as skin involvement is common and often the earliest involved site of disease [2].